News

Dr. Panzara has extensive credentials in drug research and clinical development, and this appointment will strengthen Immunic's leadership team in the field of innovative therapy development. Dr. Panzara has led multiple major clinical projects and achieved significant results in therapeutic areas such as neuroscience and immunology. His addition is expected to accelerate the clinical advancement of Immunic’s pipeline drugs and inject new professional perspectives into the company's strategic planning. This personnel change demonstrates Immunic's determination to continuously enhance its R&D capabilities and advance the global development of its candidate drugs. The company stated that Dr. Panzara’s industry experience and scientific insight will provide vital support for the development of innovative therapies for autoimmune and inflammatory diseases.

The study results indicate that the ADA formed in treated patients does not alter the absorption, distribution, and clearance of the drug within the body, while maintaining the expected pharmacological effects. This discovery provides crucial support for the ongoing development of related drugs by certain exchanges, alleviating potential concerns about antibody interference with drug efficacy. Notably, monitoring of PK parameters (including area under the drug concentration-time curve, peak concentration, etc.) and PD indicators (such as biomarker changes) during the trial shows that regardless of whether patients develop anti-drug antibodies, their drug exposure levels and pharmacological responses remain stable. This conclusion lays a solid foundation for the design of subsequent clinical trials and drug applications.

According to the latest strategic outlook, this equipment leasing giant plans to gain a competitive edge during the upswing in capital expenditure within the construction industry. Company management stated that they have formulated a targeted expansion strategy, focusing on capturing increased investments in infrastructure construction and commercial real estate sectors.